SRPT - Sarepta Therapeutics Inc

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by StockJock-e, Apr 6, 2016.

  1. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    Strange timing, but longs are not complaining!
     
  2. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    Holding yesterdays gains pretty nicely so far
     
  3. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,448
    Likes Received:
    3,268
    Analyst Upgrade/Downgrade Update

    Brokerage firm:
    Credit Suisse
    Change: Coverage Initiated
    Previous Rating: N/A
    Current Rating: Outperform
    Previous Price Target: N/A
    Current Price Target: $68
     
  4. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    Great move off $30 support!
     
  5. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    8,448
    Likes Received:
    3,268
    Down over 6% on missed earnings and a downgrade

    upload_2017-3-1_8-10-34.png
     
  6. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    Big day here, check out this move!

    Watch out for sellers before lunch IMO
     
  7. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    Definitely a short squeeze here after yesterdays move.
     
  8. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    +20%

    Sarepta Therapeutics SRPT are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations in its earnings report yesterday after the bell." data-reactid="11">On Thursday, shares of Sarepta Therapeutics SRPT are surging, up almost 24% to $42.14 per share in morning trading after the biotech company reported second-quarter revenues that blew past expectations in its earnings report yesterday after the bell.

    Sarepta reported quarterly revenue of $35 million, which was $13 million above what analysts at Thomson Reuters expected and reflected sequential growth of 115%. This outperformance was mainly due to strong sales from Sarepta’s Duchenne muscular dystrophy (DMD) drug, Exondys 51.

    The company also incurred a narrower-than-expected loss in Q2, reporting earnings of a loss of 65 cents per share and beating the Zacks Consensus Estimate of a loss of 92 cents per share. Investors should note that loss per share excludes restructuring costs and gain from asset sale but includes the impact of share-based compensation expenses.
     
  9. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    +6%, wow buyers still at it!
     
  10. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    9,524
    Likes Received:
    3,526
    New 52wk highs!

    Boom!
     
  11. KyleLennon

    KyleLennon Member

    Joined:
    Mar 25, 2018
    Messages:
    248
    Likes Received:
    34
    Sarepta has been pursuing strategic collaborations for the development of its disease- modifying DMD pipeline ever since it gained approval for Exondys 51. Ezutromid is currently being evaluated in a phase II study, PhaseOut DMD, with 24-week and 48-week biopsy data anticipated in first and third quarter of 2018, respectively.

    What's more, its quarterly revenue growth was 956.60%, super impressive.
     

Share This Page